The global Hutchinson Gilford progeria syndrome market is expected to garner a market value of US$ 103.07 Billion in 2023 and is expected to accumulate a market value of US$ 233.05 Billion by registering a CAGR of 8.5% in the forecast period 2023 to 2033. The growth of the Hutchinson-Gilford progeria syndrome market can be attributed to the increasing population of the globe which in turn is contributing to more cases of the illness. The market for Hutchinson Gilford progeria syndrome registered a CAGR of 5.5% in the historical period 2017 to 2022
Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. With continuous research and development efforts, the medication and treatment are expected to shape the market for the Hutchinson-Gilford progeria syndrome market in the upcoming years.
The affected children develop a characteristic facial experience including prominent eyes, a small chin, protruding ears, thin lips, and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experience severe hardening of the arteries (arteriosclerosis) from childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 103.07 Billion |
| Anticipated Forecast Value (2033) | US$ 233.05 Billion |
| Projected Growth Rate (2023 to 2033) | 8.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Hutchinson Gilford progeria syndrome reflected a value of 5.5% during the historical period, 2017 to 2022.
Hutchinson-Gilford progeria is a rare condition that affects about one in four Billion new-borns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any effective treatment therapy discovered for Hutchinson-Gilford progeria syndrome. The treatments available focused mostly on reducing cardiovascular symptoms and growth abnormalities.
With more efforts for investing in developing medication for treating the ailment, innovative treatment is expected to launch in the upcoming years. Thus, the market for Hutchinson Gilford progeria syndrome is expected to register a CAGR of 8.5% in the forecast period 2023 to 2033.
Genetic changes leading to extensive study of Hutchinson-Gilford progeria syndrome
In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone and Sulforaphane helped in reducing the symptoms and prolonging a child’s life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that was demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate the degradation of progerin.
Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier – the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.
Researchers are working to determine how genetic changes are further leading to the characteristic features of Hutchinson-Gilford progeria syndrome. Continuous advancement in research with an increased understanding of human aging will provide valuable insights and aid in the treatment of this disease.
Extensive research activities resulting in the innovation of medication for treating Hutchinson-Gilford progeria syndrome
Research and development activities by major institutes to find novel therapies for age-related conditions are expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from the Houston Methodist Research Institute at the Texas Medical Center focused on using RNA therapeutics - treatment that is focused on ribonucleic acids, a substance found in all living cells - to slow, and possibly reverse Hutchinson-Gilford Progeria.
Similarly, in July 2019, researchers from the University of Oviedo in Spain found that fecal microbiota transplants can help prematurely old mice live longer. The research may help to design targeted probiotic treatments for age-related conditions such as Hutchinson-Gilford Progeria in humans.
Moreover, in March 2019, researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Universidad de Oviedo identified a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome. The newly identified therapeutic target can be used for blocking early atherosclerosis in progeria.
Principal Consultant
Unavailability of proper medication affecting the growth of Hutchinson-Gilford progeria syndrome
The unavailability of accurate medication and treatment for Hutchinson-Gilford progeria syndrome is the major factor hindering the growth of the market. Despite investing money into research and development, favorable results have not been gained through the same. This has led to a delayed and prolonged process for finding the correct treatment to cure Hutchinson-Gilford's progeria syndrome.
Furthermore, Hutchinson-Gilford progeria syndrome starts showing signs and its presence after two years. This has led to an overall delayed process of taking treatments by patients. Furthermore, the lack of knowledge by healthcare professionals and people is creating obstacles to the growth of the Hutchinson-Gilford progeria syndrome market.
Find the Children initiative supporting treatment for Hutchinson-Gilford Progeria Syndrome
In terms of market share and revenue, North America is expected to dominate the Progeria treatment market during the forecast period. This is owing to the improved healthcare infrastructure and the strong presence of key players in the region.
For instance, The USA-based Progeria Research Foundation is the only organization in the world dedicated to finding treatments and a cure for children with Progeria. They launched the 'Find the Children' initiative to search the world for undiagnosed children with Progeria so that they, too, can receive the specialized care they require. Thus, North America is expected to possess a 45% market share of the Hutchinson-Gilford progeria syndrome market in 2023.
Research and development activities for innovating treatments for Hutchinson-Gilford progeria syndrome
The Asia Pacific region is expected to be the fastest-growing market during the forecast period. Significant growth in the Asia Pacific market is attributed to an increase in healthcare expenditure, an increase in government efforts to support medical tourism, and rapid advances in the biotechnology industry.
Increased healthcare spending by a large segment of the population in emerging markets such as India and China is expected to fuel the region's progeria market during the forecast period. Thus, Asia Pacific is expected to hold a 40% market share of the Hutchinson-Gilford progeria syndrome market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end-user, the Hutchinson Gilford progeria syndrome market is segmented into Hospitals & Surgical Centres, Specialty Clinics, Others
The hospitals & surgical centers segment is expected to hold the largest market share for Hutchinson Gilford progeria syndrome. This is owing to the availability of various diagnostics, testing equipment, and healthcare expertise in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of Hutchinson-Gilford progeria syndrome.
In addition, initiatives by government authorities to support the treatment of Hutchinson Gilford progeria syndrome, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Hutchinson Gilford progeria syndrome. Thus, hospitals & surgical centers are expected to hold 50% market share for the Hutchinson Gilford progeria syndrome market in 2023.
Key players in the Hutchinson-Gilford progeria syndrome market are Eiger BioPharmaceuticals, Teva Pharmaceutical, Inc., Amgen, Sanofi, Novartis AG, Schering-Plough, PRG Science & Technology Co., Ltd, Micro Interventional Devices Inc, Boston Scientific Corporation, CryoLife Inc.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 103.07 Billion |
| Market Value in 2033 | US$ 233.05 Billion |
| Growth Rate | CAGR of 8.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
Trends include advances in understanding the genetic basis of HGPS, potential targeted therapies, and improved patient care.
HGPS leads to various symptoms including growth failure, cardiovascular issues, and skeletal abnormalities, typically resulting in a shortened lifespan.
Challenges include limited patient numbers for clinical trials, high treatment costs, and the need for specialized medical care due to the rarity of the syndrome.
The Medical and Healthcare Industry is the Key Consumer of the Hutchinson-Gilford Progeria Syndrome Market
India, China, and Japan are the Key Asian Countries in the Hutchinson-Gilford Progeria Syndrome Market.
1. Executive Summary | Hutchinson Gilford Progeria Syndrome (HGPS) Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Farnesyltransferase Inhibitor (FTI)
5.3.2. MRI scan
5.3.3. Hearing tests
5.3.4. Cardiovascular
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033
6.3.1. Hospitals & Surgical Centres
6.3.2. Specialty Clinics
6.3.3. Others
6.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. South Asia
7.3.5. East Asia
7.3.6. Oceania
7.3.7. Middle East and Africa(MEA)
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End-user
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End-user
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End-user
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End-user
10.4. Key Takeaways
11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. India
11.2.1.2. Malaysia
11.2.1.3. Singapore
11.2.1.4. Thailand
11.2.1.5. Rest of South Asia
11.2.2. By Treatment
11.2.3. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End-user
11.4. Key Takeaways
12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.2. By Treatment
12.2.3. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End-user
12.4. Key Takeaways
13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Australia
13.2.1.2. New Zealand
13.2.2. By Treatment
13.2.3. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Treatment
13.3.3. By End-user
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of Middle East and Africa(MEA)
14.2.2. By Treatment
14.2.3. By End-user
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Treatment
14.3.3. By End-user
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Treatment
15.1.2.2. By End-user
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Treatment
15.2.2.2. By End-user
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Treatment
15.3.2.2. By End-user
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Treatment
15.4.2.2. By End-user
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Treatment
15.5.2.2. By End-user
15.6. United Kingdom
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Treatment
15.6.2.2. By End-user
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Treatment
15.7.2.2. By End-user
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Treatment
15.8.2.2. By End-user
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Treatment
15.9.2.2. By End-user
15.10. India
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Treatment
15.10.2.2. By End-user
15.11. Malaysia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Treatment
15.11.2.2. By End-user
15.12. Singapore
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Treatment
15.12.2.2. By End-user
15.13. Thailand
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Treatment
15.13.2.2. By End-user
15.14. China
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Treatment
15.14.2.2. By End-user
15.15. Japan
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Treatment
15.15.2.2. By End-user
15.16. South Korea
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Treatment
15.16.2.2. By End-user
15.17. Australia
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Treatment
15.17.2.2. By End-user
15.18. New Zealand
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Treatment
15.18.2.2. By End-user
15.19. GCC Countries
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Treatment
15.19.2.2. By End-user
15.20. South Africa
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Treatment
15.20.2.2. By End-user
15.21. Israel
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Treatment
15.21.2.2. By End-user
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Treatment
16.3.3. By End-user
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Eiger BioPharmaceuticals
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Teva Pharmaceutical, Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Amgen
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Sanofi
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Novartis AG
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Schering-Plough
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. PRG Science & Technology Co., Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Micro Interventional Devices Inc.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Boston Scientific Corporation
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. CryoLife Inc.
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Healthcare
January 2023
REP-GB-16359
297 pages
Explore Healthcare Insights
View Reports
Hutchinson-Gilford Progeria Syndrome Market
